Investors are increasingly turning to Swing Trader: High Volatility Stocks for Active Trading (TA&FA), to improve their trading performance, and one such robot has been generating impressive returns for investors. In the previous month, an AI trading robot generated a 5.80% profit for BNGO.
On Thursday, March 2, 2023, Cooper Companies, a major producer of contact lenses and medical equipment, is scheduled to release its financial results. The business has had a successful year, and its stock price has been steadily rising. Recent market signs, however, indicate that the stock may be changing from an upward to a bearish trend. The 10-day RSI Indicator for COO moved out of...
EssilorLuxottica SA posted third quarter revenue of 6.39 billion euros ($6.25 billion), which is +17% higher (+8.2% at constant currency rates). The figure is in line with analysts' expectations (based on FactSet poll). The luxury eyecare company’s revenue from North America rose +20.5% (+3.4% at constant currency rates) from the year-ago quarter, while those from EMEA were up +7.6%...
Hexo posted its fiscal third-quarter revenue of C$45.6 million, which is +101% higher from a year earlier. However, it fell -14% quarter-over-quarter. The cannabis company reported an adjusted loss of C$-0.045 a share, in line with expectations of analysts polled by Investing.com. According to the company, its 450 staff retrenchments will lower sales and administrative expenses by 30%, or...
Cooper Companies reported its quarterly earnings results that surpassed analysts’ expectations. The medical device company’s earnings came in at $3.24 a share for the quarter, above the Zacks’ consensus estimate of $3.10. The figure was $3.17 per share a year ago. Cooper Companies revenue rose +15.7% from the year-ago quarter to $787.20 million, also exceeding analyst estimates of $739.30...
Cannabis company HEXO Corp. posted a loss of -$93.3 million or -37 cents in its fiscal first quarter. Losses, adjusted for asset impairment costs and costs related to mergers and acquisitions, were -9 cents per share. The result was better than the -10 cents per share loss expected by analysts surveyed by Zacks Investment Research. The company’s adjusted revenue for the quarter came in at...
Hexo reported its latest quarterly revenue that beat analysts’ expectations.
The cannabis company’s revenue for the quarter ended April 30 came in at $16.3 million, compared to the $14.9 million that Zacks Investment Research had predicted.The result also surpassed FactSet’s estimate of just under $15 million.
The company’s revenue got a major boost from sales of the "Original Stash" brand.
Overall, adult-use cannabis revenue climbed to $22.07 million, up from a little over $17 million in the previous quarter and $10.8 million in the year-ago quarter.
Hexo’s gross margins increased by 40%.
Baxter International Inc. reported preliminary third-quarter 2019 revenues of $2.85 billion, which were lower than the Zacks Consensus Estimate of $2.86 billion.However, the figure was +3% higher compared to the year-ago quarter, on a reported basis.
Intuitive Surgical beat analysts' estimates on earnings for its latest quarter, while also surpassing revenue expectations.
The robotic surgery company reported earnings of $3.43 a share in the third quarter, compared to analysts’ expectation of $2.96 (based on survey by Zacks Investment Research).
Intuitive Surgical had a +21.2% gain in adjusted EPS during the third quarter compared to the same period a year ago.
Revenue increased +22.5% year-over-year for the to $1.13 billion, which exceeded the $1.06 billion expected by analysts (polled by Zacks).
"
The cannabis company said that it expects fourth-quarter revenue to range between C$14.5 million to C$16.5 million ($10.9 million to $12.4 million), below Wall Street's forecast of C$24.8 million ($18.6 million).For the full-year, the company projects revenue to range between C$46.5 million and C$48.5 million ($34.9 million to $36.4 million).
Hexo was withdrawing its 2020 financial outlook due to regulatory uncertainty across the pan-Canadian system, and jurisdictional decisions that it thinks will limit the availability and types of cannabis derivative products.
"While we are disappointed with these results, we are making significant changes to our sales and operations strategy to drive future results," said Sebastien St-Louis, Hexo's CEO and co-founder.
On Monday, Michael Monahan, Hexo’s chief financial officer, resigned from the company, due to his "family's needs."
AngioDynamics shares plummeted on Thursday, after the company released its latest guidance for the full-year.
The medical devices maker announced the purchase of Israeli laser company Eximo for $46 million up front, with up to another $20 million conditional upon Eximo meeting its technical and revenue milestones.
Following the acquisition, AngioDynamics now expects earnings for fiscal 2020 to range between 10 cents and 15 cents a share – a range lower than analysts’ expectation of 26 cents.
Angio CEO Jim Clemmer indicated that the acquisition of Eximo would usher in a remarkable, foundational technology for its portfolio in a way that transforms the way caregivers provide treatment to patients with PAD. "The market is ripe for disruption, and the level of precision, safety, and efficiency offered to physicians by this laser technology creates a substantially differentiated alternative to legacy atherectomy devices," Clemmer said.
Separa
Aerie Pharmaceuticals, Inc.announced that it has initiated the dosing in a phase II study on netarsudil ophthalmic solution in Japan for reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Read more...
Recro Pharma, Inc., a specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, posted revenue of $77.3 million and $71.8 million for the years ended December 31, 2018 and 2017, respectively.The increase of $5.5 million in 2018 revenue versus 2017 revenue was due to an increase in product sales to various commercial partners and increased profit sharing, including the impact from the new revenue recognition standard, recognized from one of our commercial partners.
“As we await the upcoming review decision from the U.S. Food and Drug Administration (FDA) for intravenous (IV) meloxicam, we are building our commercial infrastructure and preparing for our first potential product launch during 2019,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma.